Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia.

Ohnuma T, Sakai Y, Maeshima H, Higa M, Hanzawa R, Kitazawa M, Hotta Y, Katsuta N, Takebayashi Y, Shibata N, Arai H.

Int J Psychiatry Med. 2012;44(1):17-27.

PMID:
23356091
2.

Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).

Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, Kida S, Shibata N, Suzuki T, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1905-12. doi: 10.1016/j.pnpbp.2008.07.022. Epub 2008 Sep 16.

PMID:
18835577
3.

Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.

Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, Ohi K, Umeda-Yano S, Ito A, Ohmori T, Hashimoto K, Takeda M.

Neurosci Lett. 2014 Oct 17;582:93-8. doi: 10.1016/j.neulet.2014.08.052. Epub 2014 Sep 10.

PMID:
25218715
4.

Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia.

Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY.

Int J Neuropsychopharmacol. 2005 Sep;8(3):451-5. Epub 2005 Apr 7.

PMID:
15817136
5.

Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.

Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY.

Int J Neuropsychopharmacol. 2004 Mar;7(1):1-8. Epub 2004 Jan 13.

PMID:
14720317
6.

Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.

Hons J, Vasatova M, Cermakova E, Doubek P, Libiger J.

J Psychiatr Res. 2012 Jun;46(6):811-8. doi: 10.1016/j.jpsychires.2012.03.015. Epub 2012 Apr 13.

PMID:
22502820
7.

Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP).

Hatano T, Ohnuma T, Sakai Y, Shibata N, Maeshima H, Hanzawa R, Suzuki T, Arai H.

Psychiatry Res. 2010 May 15;177(1-2):27-31. doi: 10.1016/j.psychres.2010.02.014. Epub 2010 Mar 11.

PMID:
20226539
8.

Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia.

Ohnuma T, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):29-39. doi: 10.1016/j.pnpbp.2010.08.027. Epub 2010 Sep 7. Review.

PMID:
20828596
9.

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M.

Arch Gen Psychiatry. 1999 Jan;56(1):29-36.

PMID:
9892253
10.

[Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].

Strzelecki D, Rabe-Jabłońska J.

Psychiatr Pol. 2010 May-Jun;44(3):395-404. Polish.

PMID:
20672518
11.

Profiling cognitive impairment in treatment-resistant schizophrenia patients.

Frydecka D, Beszłej JA, Gościmski P, Kiejna A, Misiak B.

Psychiatry Res. 2016 Jan 30;235:133-8. doi: 10.1016/j.psychres.2015.11.028. Epub 2015 Nov 18.

PMID:
26706131
12.

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.

Am J Psychiatry. 2007 Oct;164(10):1593-602.

PMID:
17898352
13.

The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG.

Am J Psychiatry. 2009 Sep;166(9):1055-62. doi: 10.1176/appi.ajp.2009.09010017. Epub 2009 Jul 1.

14.

Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type.

Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U.

Am J Psychiatry. 2005 Sep;162(9):1738-40.

PMID:
16135636
15.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
16.

D-alanine added to antipsychotics for the treatment of schizophrenia.

Tsai GE, Yang P, Chang YC, Chong MY.

Biol Psychiatry. 2006 Feb 1;59(3):230-4. Epub 2005 Sep 9.

PMID:
16154544
17.

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M.

Arch Gen Psychiatry. 2003 Jun;60(6):572-6.

PMID:
12796220
18.

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.

Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.

J Clin Psychiatry. 2012 Jun;73(6):e728-34. doi: 10.4088/JCP.11m07031.

PMID:
22795211
19.

High dose D-serine in the treatment of schizophrenia.

Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, D'Souza C, Saksa J, Woods SW, Javitt DC.

Schizophr Res. 2010 Aug;121(1-3):125-30. doi: 10.1016/j.schres.2010.05.012. Epub 2010 Jun 11.

20.

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.

Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC.

Biol Psychiatry. 2004 Jan 15;55(2):165-71.

PMID:
14732596

Supplemental Content

Support Center